How to Get Lantus in Connecticut

What Is Lantus and Why Connecticut Patients Need a Prescription

Lantus is a long-acting basal insulin analog approved by the FDA for once-daily subcutaneous injection in adults and pediatric patients aged 6 and older with type 1 diabetes, and in adults with type 2 diabetes. Insulin glargine works by precipitating at physiological pH, releasing a steady, peakless supply of insulin over approximately 24 hours. [1]

Because insulin glargine is a Schedule-exempt but prescription-only medication under Connecticut General Statutes, no patient may receive it from a licensed pharmacy without a valid written or electronic order from an authorized prescriber. [2] That single legal requirement is the starting point for every access pathway described in this article.

The cardiovascular safety of long-term insulin glargine use was established in the ORIGIN trial (N=12,537), published in the New England Journal of Medicine in 2012. Participants randomized to insulin glargine showed a neutral effect on major cardiovascular events compared with standard care over a median 6.2-year follow-up, with a hazard ratio of 1.02 (95% CI 0.94 to 1.11). [3] That finding reassured clinicians prescribing basal insulin across long time horizons, which is the typical situation for most Connecticut patients managing type 2 diabetes.

Biosimilar glargine products (Basaglar, Semglee) carry the same active ingredient and FDA-approved indications. Semglee received full interchangeable biosimilar designation from the FDA in July 2021, the first insulin to do so. [4] A Connecticut pharmacist may substitute an interchangeable biosimilar unless the prescriber explicitly writes "dispense as written."

Who Can Prescribe Lantus in Connecticut

Any Connecticut-licensed MD, DO, advanced practice registered nurse (APRN) with prescriptive authority, or physician assistant (PA) working under a supervising physician may write a Lantus prescription. Connecticut does not require a separate DEA number for insulin because it is not a controlled substance. [5]

APRNs in Connecticut hold full practice authority in certain settings under Connecticut General Statutes Section 20-87a, meaning they may prescribe independently without a collaborative agreement in many telehealth contexts. [6] PAs must operate under a supervision agreement but are otherwise unrestricted in prescribing insulin.

Endocrinologists, primary care physicians, and internal medicine specialists all routinely write Lantus prescriptions. A diabetes-specific specialist is not required by law or by any Connecticut Medicaid rule before a basal insulin prescription is issued for type 2 diabetes, though some insurance prior authorizations ask for documentation that oral agents were tried first.

Connecticut Prescriber Authority Summary

| Credential | Independent Rx Authority | Notes | |---|---|---| | MD / DO | Yes | No additional requirements | | APRN (with prescriptive authority) | Yes (in most settings) | Per CGS 20-87a | | PA | Supervised | Requires supervision agreement | | CNM | Yes for obstetric patients | Per CGS 20-86c |

Getting Lantus Through a Connecticut Telehealth Provider

Telehealth prescribing of insulin glargine is fully legal in Connecticut. The state's telehealth statute (Public Act 21-9) removed the requirement for a prior in-person visit, so a new patient may complete a video or asynchronous encounter with a licensed Connecticut provider and receive a Lantus prescription on the same day if clinical criteria are met. [7]

Three categories of telehealth providers serve Connecticut diabetes patients:

Dedicated diabetes telehealth platforms. Several national platforms hold Connecticut medical licenses and can prescribe basal insulin after reviewing uploaded labs, A1C results, and a glucose log. Visits typically cost $50 to $150 without insurance.

Primary care telehealth. Large telehealth networks with Connecticut-licensed physicians offer same-day or next-day appointments that include insulin prescribing for existing diabetes diagnoses.

HealthRX provider network. HealthRX-affiliated clinicians licensed in Connecticut conduct synchronous video visits and can transmit an electronic prescription directly to a Connecticut pharmacy or mail-order pharmacy of the patient's choice. A prior in-person visit is not required under Connecticut law. [7]

The American Diabetes Association 2024 Standards of Care state that "all people with diabetes deserve access to evidence-based, comprehensive diabetes care," and specifically endorse telehealth delivery as a mechanism to reduce disparities. [8] Connecticut's telehealth-friendly regulatory environment aligns with that position.

After a completed telehealth visit, most Connecticut mail-order pharmacies fill and ship Lantus within one to three business days. CVS, Walgreens, and independent Connecticut pharmacies all accept electronic Lantus prescriptions.

Labs Required Before Starting Lantus in Connecticut

A Connecticut provider will order baseline labs before or shortly after initiating insulin glargine. These are not arbitrary paperwork. They establish the correct starting dose and detect conditions that change insulin requirements substantially.

Fasting plasma glucose. The most direct measure of how much basal insulin coverage is needed. Most providers use a fasting glucose persistently above 130 mg/dL as a threshold for initiating basal insulin in type 2 diabetes, consistent with ADA 2024 pharmacotherapy guidelines. [9]

HbA1c. A single HbA1c reading places the patient on the glycemic spectrum and guides the starting dose. The ADA target for most non-pregnant adults is <7.0% (53 mmol/mol), though individualization is expected. [9]

Comprehensive metabolic panel (CMP). Renal function affects insulin clearance. Estimated GFR below 30 mL/min/1.73 m² does not contraindicate glargine but may require dose reduction and more frequent glucose monitoring. [1]

Thyroid-stimulating hormone (TSH). Hypothyroidism raises insulin resistance; hyperthyroidism lowers it. Either condition, if undetected, will make Lantus titration unpredictable. [10]

C-peptide (for new-onset or uncertain diagnosis). A fasting C-peptide below 0.6 ng/mL in a symptomatic adult suggests type 1 physiology, which changes the dosing strategy considerably. [11]

Labs can be ordered through a Connecticut LabCorp or Quest Diagnostics location, through a hospital outpatient lab, or through a telehealth platform's integrated lab-ordering service that partners with in-state draw sites. Results are typically available within 24 to 48 hours and can be uploaded to the telehealth chart electronically.

Starting Dose and Titration Protocol

Insulin glargine is not a fixed-dose medication. The starting dose and titration schedule depend on baseline fasting glucose, body weight, current oral agents, and whether the patient has type 1 or type 2 diabetes. [1]

Type 2 diabetes (insulin-naive). The ADA 2024 Standards recommend starting at 10 units subcutaneously once daily or 0.1 to 0.2 units/kg/day, then titrating by 2 units every three days until fasting glucose reaches the target range of 80 to 130 mg/dL. [9]

Type 1 diabetes. Total daily insulin dose is calculated at 0.4 to 0.5 units/kg/day, with roughly 50% allocated to basal glargine and the remainder split across mealtime rapid-acting insulin. [12]

Switching from NPH or another basal insulin. When converting from once-daily NPH, the glargine dose is typically the same unit count as the NPH dose. Conversion from twice-daily NPH involves a 20% dose reduction to account for glargine's longer, flatter action profile and to reduce hypoglycemia risk. [1]

Patients should inject glargine at the same time each day, subcutaneously into the abdomen, thigh, or upper arm. Rotating injection sites within a region reduces lipohypertrophy, which can blunt insulin absorption unpredictably. [13]

Connecticut Medicaid (HUSKY Health) Coverage for Lantus

Connecticut Medicaid, administered as HUSKY Health (Plans A, B, C, and D), covers insulin glargine for both type 1 and type 2 diabetes with prior authorization. Without PA, the claim will be denied at the pharmacy. [14]

What prior authorization requires. A typical Connecticut Medicaid PA for Lantus asks for:

1. Confirmed diabetes diagnosis (ICD-10 code E10.x for type 1 or E11.x for type 2).
2. Current HbA1c and fasting glucose values.
3. For type 2 patients: documentation that at least one non-insulin agent was tried and either failed to achieve glycemic control or is contraindicated.
4. Prescriber name, NPI, and Connecticut license number.
5. Requested dose and quantity (typically 10 mL vials or 3 mL SoloSTAR pens, 30-day supply).

A prescriber's office, or a telehealth platform's clinical support team, typically submits the PA to Connecticut Medicaid within 24 hours of the visit. Standard PA decisions are returned within three business days under Connecticut insurance regulations. Urgent PA requests (when the patient has no insulin on hand) may be processed within 24 to 72 hours. [14]

The Endocrine Society's 2022 clinical practice guideline on insulin therapy states that "payers and pharmacy benefit managers should not require failure of multiple basal insulin products before approving the initially prescribed agent when clinical rationale exists." [15] That position supports appeals when a plan demands NPH trial first.

Private Insurance and Commercial Plans in Connecticut

Most Connecticut commercial plans (Aetna, Cigna, Anthem, ConnectiCare, Harvard Pilgrim) cover insulin glargine on Tier 2 or Tier 3 of their formularies. Step therapy requirements, which mandate an NPH or biosimilar trial before brand-name Lantus, are common. [16]

Connecticut has a step therapy override law (Public Act 17-172) that requires insurers to approve a step therapy exception within 72 hours if the prescriber documents that the required step drug is contraindicated, caused an adverse reaction, or is expected to be ineffective based on the patient's clinical history. [17] A telehealth provider can submit this documentation during or immediately after the visit.

For patients without insurance or with a high-deductible plan, Sanofi's Insulins Valyou savings program caps monthly out-of-pocket costs for Lantus at $99 for eligible patients. The program is accessible at Sanofi's patient assistance page. GoodRx pricing for a 10 mL vial of Lantus U100 at Connecticut pharmacies ranges from approximately $140 to $290 depending on the chain and zip code.

A 2021 analysis in JAMA Internal Medicine found that among U.S. adults with insulin-treated diabetes, 16.5% reported rationing insulin due to cost in the prior 12 months. [18] Connecticut's insulin cost-sharing cap law (Public Act 21-27) limits cost sharing for covered insulin to $25 per 30-day supply for state-regulated commercial plans. [19]

Transferring an Existing Lantus Prescription to Connecticut

Patients relocating to Connecticut from another state face a straightforward process. A valid out-of-state prescription for insulin glargine may be transferred to a Connecticut-licensed pharmacy once, per Connecticut pharmacy law. [20] The receiving pharmacist contacts the originating pharmacy to verify and transfer the remaining refills.

If the prescription is expired or has no refills remaining, a Connecticut-licensed provider must issue a new prescription. A telehealth visit works for this purpose. The provider will ask for the patient's prior prescription information, recent glucose logs or A1C results, and any records of prior adverse reactions. No law requires an in-person visit to renew an insulin prescription in Connecticut.

Patients using a mail-order pharmacy based outside Connecticut should verify that the pharmacy holds a Connecticut non-resident pharmacy permit, issued by the Connecticut Drug Control Division. Most major mail-order pharmacies (Express Scripts, OptumRx, CVS Caremark specialty) hold this permit. [21]

503A Compounding Pharmacies and Insulin Glargine in Connecticut

A 503A pharmacy is a state-licensed, patient-specific compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Connecticut-licensed 503A pharmacies may compound insulin glargine preparations for individual patients when there is a valid prescription and a documented clinical need that the commercially available product cannot meet. [22]

Common reasons a 503A compound might be ordered include a patient's documented allergy to an excipient in the commercial Lantus formulation, or the need for a concentration not commercially available for pediatric dosing. Routine cost-reduction is not a recognized 503A indication under FDA policy. [22]

Patients considering 503A insulin should confirm that the pharmacy is licensed with the Connecticut Drug Control Division and is accredited by PCAB (Pharmacy Compounding Accreditation Board) or a recognized equivalent. The FDA maintains a list of compounding pharmacies that have received warning letters, which patients and providers may consult. [23]

Storing Lantus After It Arrives

Lantus vials and pens that have not been opened should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) and remain potent until the expiration date on the label. [1] Once opened (first use or punctured), a vial may be kept at room temperature below 86°F (30°C) or in the refrigerator for up to 28 days. An open SoloSTAR pen should be kept at room temperature below 86°F (30°C) for up to 28 days and should never be refrigerated after first use. [1]

Connecticut summers regularly reach temperatures above 90°F. Patients who travel or lack reliable refrigeration should use an insulin travel case with a cooling insert rated for 28-day use or the Frio evaporative cooling wallet, which maintains insulin below 86°F for at least 45 hours in ambient temperatures up to 104°F. [24]

Never freeze Lantus. Frozen insulin should be discarded. [1]

Common Adverse Effects and When to Contact a Connecticut Provider

The most clinically significant adverse effect of insulin glargine is hypoglycemia. In the ORIGIN trial (N=12,537), the annualized rate of severe hypoglycemia (requiring third-party assistance) was 1.00 per 100 patient-years in the glargine group vs. 0.31 per 100 patient-years in the standard-care group. [3]

Mild hypoglycemia (blood glucose below 70 mg/dL) is more frequent. Patients should keep 15 to 20 grams of fast-acting carbohydrate available and follow the 15-15 rule: consume 15 grams of carbohydrate, wait 15 minutes, recheck glucose, repeat if still below 70 mg/dL. [25]

Other adverse effects include injection-site reactions (3 to 4% of patients), lipohypertrophy with poor site rotation, and weight gain averaging 1.6 kg over six months in insulin-naive type 2 patients. [3] Allergic reactions to Lantus are rare; the metacresol preservative is the most common sensitizing agent, which is one documented rationale for a 503A compound. [1]

A Connecticut patient should contact their prescriber or a telehealth provider promptly if fasting glucose consistently exceeds 180 mg/dL despite titration, if hypoglycemia requiring third-party assistance occurs, or if injection-site changes suggest lipohypertrophy affecting insulin absorption. [9]

How Long Before Lantus Takes Full Effect

Insulin glargine has an onset of approximately one to two hours after the first injection. The full basal steady state, where 24-hour glucose-lowering activity is consistent from day to day, is typically reached after two to three days of once-daily dosing. [1]

Visible improvements in fasting glucose generally appear within 48 to 72 hours of starting a correctly dosed regimen. A meaningful drop in HbA1c, however, requires six to eight weeks of stable dosing because that marker reflects average glucose over approximately 90 days. The ORIGIN trial demonstrated that glargine-treated patients achieved a median HbA1c of 6.2% compared to 6.5% in the standard-care arm at six months. [3]

Patients should not adjust the Lantus dose more frequently than every three days, as more rapid titration prevents the glucose readings from stabilizing enough to guide the next dose change. [9]